



RENEGOTIATED LICENSING AGREEMENT FOR HUMAN INSULIN POSTIONS SCIGEN STRONGLY FOR INTERNATIONAL SALES GROWTH

Singapore and Sydney. Friday 16th June 2006. SciGen Limited (ASX:SIE) has renegotiated the terms of its licensing agreement with Ferring S.A for the manufacture and sale of recombinant human insulin resulting in an expansion of rights and a stronger sales position globally.

The two key changes to the license agreement are:

- Ferring has granted SciGen a royalty free license for sales of injectable recombinant human insulin for the remaining life of the license, approximately 15 years. SciGen has agreed to pay US\$3.0 million consideration due in two instalments over the next six months; and
- The removal of an international non-compete condition for the injectable insulin product.

The royalty free license will deliver significant cost savings to SciGen in the future and the company expects to recover the upfront payment within five years.

The non-compete condition is very significant to SciGen's ability to increase its international sales channels.

SciGen has been released from its obligation to refrain from engaging in competition activities in respect to the manufacturing and selling of injectable human insulin globally.

"SciGen now has the freedom to acquire and manufacture a second, non-Ferring, recombinant human insulin in its newly acquired facility in India for the worldwide markets including Western Europe, the USA & Canada, Latin America & the Caribbean's, Middle-East and Africa," said CEO Mr Saul Mashaal.

"The new arrangement gives us much more flexibility to consider new products to assist us in achieving rapid growth in the coming years."

SciGen will continue to pay a minimal royalty to Ferring for sales of non-injectable Insulin in the Asia Pacific region.

"With our recent worldwide acquisition of two important biogeneric technologies (also known as biosimilars) GCSF & EPO announced recently, and third generation vaccine Sci-B-Vac™, SciGen has taken a giant leap forward in becoming a truly global company."

"With two manufacturing sites being erected simultaneously, one in India and another in Israel, all of our requirements for worldwide distribution of our products will be met for the foreseeable future putting us in a very strong position," Mr Mashaal concluded.

[About SciGen](#)

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and biogeneric products, which allow for faster entry into the market, as biogeneric products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with offices in Australia, USA, Korea, Vietnam, Hong Kong, and Philippines and partners in India, China, Indonesia, Israel, Poland, Austria and the Netherlands.

Further information:

Investor Relations and Media	Company
Rebecca Wilson Buchan Consulting +61 2 9237 2800 +61 417 382 391 (mobile) rwilson@bcg.com.au	Saul Mashaal Executive Vice Chairman, Founder & CEO SciGen Ltd. + 61 2 9234 1700 +65 9630 5691 (Mobile)